Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 211

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Open access
Palumbo, Antonio, Bringhen, Sara, Larocca, Alessandra, Rossi, Davide, Di Raimondo, Francesco, Magarotto, Valeria, Patriarca, Francesca, Levi, Anna, Benevolo, Giulia, Vincelli, Iolanda Donatella, Grasso, Mariella, Franceschini, Luca, Gottardi, Daniela, Zambello, Renato, Montefusco, Vittorio, Falcone, Antonietta Pia, Omedé, Paola, Marasca, Roberto, Morabito, Fortunato, Mina, Roberto, Guglielmelli, Tommasina, Nozzoli, Chiara, Passera, Roberto, Gaidano, Gianluca, Offidani, Massimo, Ria, Roberto, Petrucci, Maria Teresa, Musto, Pellegrino, Boccadoro, Mario, Cavo, Michele·2014·Journal of Clinical Oncology

Abstract

Purpose: Bortezomib-melphalan-prednisone (VMP) has improved overall survival in multiple myeloma. This randomized trial compared VMP plus thalidomide (VMPT) induction followed by bortezomib-thalidomide maintenance (VMPT-VT) with VMP in patients with newly diagnosed multiple myeloma. Patients and Methods: We randomly assigned 511 patients who were not eligible for transplantation to receive VMPT-VT (nine 5-week cycles of VMPT followed by 2 years of VT maintenance) or VMP (nine 5-week cycles without maintenance). Results: In the initial analysis with a median follow-up of 23 months, VMPT-VT improved complete response rate from 24% to 38% and 3-year progression-free-survival (PFS) from 41% to 56% compared with VMP. In this analysis, median follow-up was 54 months. The median PFS was significantly longer with VMPT-VT (35.3 months) than with VMP (24.8 months; hazard ratio [HR], 0.58; P < .001). The time to next therapy was 46.6 months in the VMPT-VT group and 27.8 months in the VMP group (HR, 0.52; P < .001). The 5-year overall survival (OS) was greater with VMPT-VT (61%) than with VMP (51%; HR, 0.70; P = .01). Survival from relapse was identical in both groups (HR, 0.92; P = .63). In the VMPT-VT group, the most frequent grade 3 to 4 adverse events included neutropenia (38%), thrombocytopenia (22%), peripheral neuropathy (11%), and cardiologic events (11%). All of these, except for thrombocytopenia, were significantly more frequent in the VMPT-VT patients. Conclusion: Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.52.0023

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 211

Metadata

Authors
Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., Patriarca, F., Levi, A., Benevolo, G., Vincelli, I. D., Grasso, M., Franceschini, L., Gottardi, D., Zambello, R., Montefusco, V., Falcone, A. P., Omedé, P., Marasca, R., Morabito, F., Mina, R., Guglielmelli, T., Nozzoli, C., Passera, R., Gaidano, G., Offidani, M., Ria, R., Petrucci, M. T., Musto, P., Boccadoro, M., & Cavo, M.
Venue
Journal of Clinical Oncology
Published
2014-03-01
Volume
32
Issue
7
Pages
634-640
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2127192057
Cited by
211
References
11
FWCI
22.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. https://app.cochat.ai/papers/10.1200/jco.2013.52.0023
The paper
Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., Patriarca, F., Levi, A., Benevolo, G., Vincelli, I. D., Grasso, M., Franceschini, L., Gottardi, D., Zambello, R., Montefusco, V., Falcone, A. P., Omedé, P., Marasca, R., Morabito, F., . . . Cavo, M. (2014). Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.52.0023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.